1
|
Athulorala S, Loku Waduge BH, Kalkat H, Saif A, Fawzy AM, Bhatia G, Kumar N, Freestone BH, Ment J, Lee K, Pitt M, Pulikal G, Basavarajaiah S. Clinical outcomes following use of sirolimus coated balloon in side-branches during provisional stent technique in true bifurcations. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.2144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Provisional stenting is the preferred strategy even in true bifurcations, however, to minimise the need for repeat revascularization of side-branches, the use of drug coated balloons has been suggested. Most of the data available in the literature are on Paclitaxel coated balloons, a drug which is almost obsolete in stents due to its cytotoxic properties. There is limited data on Limus coated balloons (SCB), a drug which is the default for all the currently available drug eluting stents. In this study, we explore the clinical outcomes following use of SCB in side-branches during provisional stent technique in true bifurcations.
Methods and results
We evaluated all de novo lesions treated with DCB for true bifurcations between March 2018 and October 2020 at our centre. The results are reported as cardiac death, target vessel myocardial infarction (TVMI), target lesion revascularisation (TLR) and MACE (combination of cardiac death, target vessel MI and TLR).
During the study period 110 patients with de novo lesions were treated with SCB for bifurcation lesions. Of them; 66 were in true bifurcations. The mean age of patients were 66.3±10.7 years, 75% (n=50) were male, 40 (61%) were in the setting of acute coronary syndrome, 52% (n=34) had diabetes and 32% (n=21) had CKD. Pre-dilatation was performed in all cases and none of them needed bailout stenting. Small vessels (<3.0 mm) accounted for 72% (n=48) of cases. Non-compliant balloons and scoring balloons to prepare the lesion was used in 51% (n=34) and 13% (n=9) of cases respectively. The mean diameter and length of SCBs were 2.6±0.4 mm and 23.2±7.3 mm respectively.
During a median follow-up of 729 days (2-years); there were no cardiac deaths, TVMI occurred in one case (2%), TLR in 3% (n=2) and the overall MACE rate was 3% (n=2). There were no documented cases of acute vessel closure
Conclusion
The results from long term follow-up with this relatively new technology of DCB in treatment of side-branch in true bifurcation is encouraging. We have demonstrated low rates of hard endpoints, TLR and MACE rates despite complex group of patients (61% ACS, 52% diabetics and 32% CKD). These results are encouraging, but going forward, we need more data from larger patient trials. In the meanwhile our data should instil confidence to adopt this technology in clinical practice.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- S Athulorala
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | | | - H Kalkat
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - A Saif
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - A M Fawzy
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - G Bhatia
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - N Kumar
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - B H Freestone
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - J Ment
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - K Lee
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - M Pitt
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - G Pulikal
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | | |
Collapse
|
2
|
Fawzy AM, Loku Waduge BH, Kalkat H, Saif AM, Athulorala S, Bhatia G, Kumar N, Freestone BH, Ment J, Lee K, Pitt M, Pulikal G, Basavarajaiah S. Does the use of scoring balloon prior to drug coated balloons improve clinical outcomes in de Novo coronary lesions? Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.2148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Aims
The use of scoring balloon prior to drug coated balloon has been proven to be effective in restenotic lesions. However, their effect in de novo lesions has not been tested. Logic tells that the use of scoring balloons should enhance the drug uptake into the vessel wall. In this study, we evaluated this concept of scoring balloon prior to DCB in de novo lesions and compared to those who were treated with a conventional approach (semi-compliant and/or non-compliant balloons).
Methods and results
We evaluated all de novo lesions treated with DCB between March 2018 and October 2020 at our centre. The results are reported as cardiac death, target vessel myocardial infarction (TVMI), target lesion revascularisation (TLR) and MACE (combination of cardiac death, target vessel MI and TLR).
During the study period 348 patients with de novo lesions were treated with DCB. Of those, 49 were predilated with scoring balloon prior to use of DCB and the remaining 299 were predilated with non-scoring balloons (semi-compliant and/or non-compliant). The majority of the baseline characteristics had no statistically significant differences (table 1), with the exception of the mean diameter of the lesions were larger in the scoring balloon group than non-scoring balloon group: 2.7±0.5 vs. 2.49±0.4; p=0.003 and mean length of lesions were longer in the non-scoring balloon group: 26±8.8 vs. 23±7.7; p=0.02. During the median follow-up of 660 days, clinical outcomes between the scoring and non-scoring balloons were; cardiac death: 0 vs. 8 (3%); p=0.5, TVMI: 2 (4%) vs. 8 (3%); p=0.9, TLR: 3 (6%) vs. 25 (8.4%); p=0.8, MACE: 4 (8%) vs. 34 (11%) p=0.7
Conclusion
There were no differences in the clinical outcomes between the two groups indicating that use of scoring balloon prior to DCB may not offer additional benefit, although this needs to be confirmed in a larger patient group.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- A M Fawzy
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | | | - H Kalkat
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - A M Saif
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - S Athulorala
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - G Bhatia
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - N Kumar
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - B H Freestone
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - J Ment
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - K Lee
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - M Pitt
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - G Pulikal
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | | |
Collapse
|
3
|
Loku Waduge BH, Kalkat H, Saif A, Fawzy AM, Athukorala S, Bhatia G, Kumar N, Freestone B, Ment J, Lee K, Pitt M, Pulikal G, Basavarajaiah S. Use of sirolimus-coated balloon in de novo small vessel coronary lesions; Long-term follow-up from a single centre registry. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.2146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Drug coated balloons (DCBs) in Europe are mainly used in restenotic lesions as endorsed by the European Society of Cardiology, with a class IA recommendation. However, some of the recent data suggest, it can also be considered in a subset of denovo lesions, especially in small vessels. Most DCBs used, are coated with Paclitaxcel. There is no data on the efficacy of Sirolimus in DCBs, the drug of choice in drug eluting stents. In this study, we report outcomes from the use of a Sirolimus coated balloon (SCB) in de novo small-vessel coronary lesions, from a single high yield centre.
Methods
A retrospective analysis was conducted on all patients treated with an SCB between March 2018 and October 2020. Follow-up was achieved with clinic visits, telephone calls and admission records. The outcomes measured include cardiac death, target-vessel myocardial-infarction (TVMI), target lesion revascularisation (TLR) and MACE (combination of cardiac death, target-vessel MI and TLR).
Results
During the study period, 279-patients (with 332-lesions) with de novo lesions were treated with an SCB. The mean age of patients was 65±12 years, 219 (79%) were male, 36% (n=100) had diabetes, 16% (n=45) had chronic kidney disease and 61% were in the setting of acute coronary syndrome (n=169). Predilatation was performed in 96% (320-lesions). Bailout stenting (with DES) was required in 5% of lesions (n=18) of which 16 were due to dissections and 2 were due to recoil >30% following DCB use. The mean diameter and length of DCBs were 2.35 mm and 26 mm respectively.
During a median follow-up of 584-days (19-months) cardiac death was reported in 8 patients (3%). Target vessel MI was in 3% (n=9), TLR per lesion was 8% (n=26) and the MACE rate was 11% (n=31). There were no documented cases of acute vessel closure.
Conclusion
The long-term outcome from the first ever study on sirolimus eluting balloons in de novo small vessel lesions appears promising with low rates of hard endpoints, and acceptable repeat rates of TLR despite a complex group of patients (50% ACS, 36% diabetics and 19% CKD) and lesion subsets (small vessel and diffuse disease). Implanting stents in these subsets renders them vulnerable to restenosis, making treatment challenging and resulting in high rates of recurrence.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
| | - H Kalkat
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - A Saif
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - A M Fawzy
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - S Athukorala
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - G Bhatia
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - N Kumar
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - B Freestone
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - J Ment
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - K Lee
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - M Pitt
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - G Pulikal
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | | |
Collapse
|
4
|
Loku Waduge BH, Kalkat H, Saif A, Fawzy AM, Athukorala S, Bhatia G, Kumar N, Freestone B, Ment J, Lee K, Pitt M, Pulikal G, Basavarajaiah S. Long term clinical outcomes from use of Sirolimus coated balloon in coronary intervention; data from a real-world population. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.2147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
The use of drug coated balloons (DCBs) in coronary intervention is escalating. There are two drugs of choice for coating either DCBs or drug eluting stents: Paclitaxel or Sirolimus. Most available DCBs are coated with Paclitaxcel, due to pre-existing, extensive data that support good clinical outcomes. With drug eluting stents both the literature and hence clinical practice favour Sirolimus over Paclitaxcel. This is due the cytostatic properties and wide therapeutic window of Sirolimus. However, there is very limited data on Sirolimus coated balloons (SCBs). We report a long-term follow-up with this relatively new technology from our centre.
Methods
A retrospective analysis was conducted on all patients treated with an SCB between March 2018 and October 2020. Follow-up was achieved with clinic visits, telephone calls and admission records. The outcomes measured include cardiac death, target-vessel myocardial-infarction (TVMI), target lesion revascularisation (TLR) and MACE (combination of cardiac death, target-vessel MI and TLR).
Results
533 patients (690-lesions) with a mean age of 65.4 (range; 37–90) were treated with an SCB. 79% (n=419) were male, 314 (59%) were in the setting of acute coronary syndrome, 40% (n=211) had diabetes and 60% (n=414) had DCB in de-novo lesions. Small vessels accounted for 59% of cases (n=406). Pre-dilatation was performed in 97% (n=670) of cases. Bailout stenting (with a drug eluting stent) was required in 6.5% lesions (n=45), of which 11 were due to dissections and 34 were due to >50% recoil following DCB use. The mean diameter and length of DCBs were 2.8 mm and 26.3 mm respectively.
During a median follow-up of 572 days (IQR: 381 - 868); cardiac death occurred in 15 patients (3%). Target vessel MI was in 4%; n=21, TLR per lesion and per patient were 10% (n=72 and n=55 respectively). The overall MACE rate was 12%. There were no documented cases of acute vessel closure.
Conclusions
The results from long term follow-up with this relatively new technology DCB are encouraging with low rates of hard endpoints and acceptable rates of TLR and MACE despite complex group of patients (59% ACS and 40% diabetics) and lesion subsets (40% restenotic lesions and 59% small vessels). However, in order to further inform clinical practice, more longer-term data on SCBs compared with Paclitaxel coated balloons is needed.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
| | - H Kalkat
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - A Saif
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - A M Fawzy
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - S Athukorala
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - G Bhatia
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - N Kumar
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - B Freestone
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - J Ment
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - K Lee
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - M Pitt
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - G Pulikal
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | | |
Collapse
|
5
|
Loku Waduge BH, Kalkat H, Saif A, Fawzy AM, Athulorala S, Bhatia G, Kumar N, Freestone B, Ment J, Lee K, Pitt M, Pulikal G, Basavarajaiah S. Use of sirolimus-coated balloon in de novo lesions; Mid-term follow-up from a single-centre registry. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.2145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Use of drug coated balloons (DCBs) in coronary intervention is escalating and the guidelines recommend its use in restenotic lesions. However, recent data suggest it can also be considered in a subset of denovo lesions especially; small vessels, ostium of an important side-branch and in patients unable to tolerate dual antiplatelet therapy for a prolonged period. Most DCBs used elute Paclitaxcel, but there is no data on Sirolimus eluting DCB, which is the drug of choice in currently available drug eluting stents. In this study, we report outcomes from the use of a Sirolimus coated balloon (SCB) in de novo coronary lesions.
Methods
We retrospectively analysed all patients treated with an SCB between April and December 2018. Results are reported as cardiac death, target vessel myocardial infarction (TVMI), target lesion revascularisation (TLR), target vessel revascularisation (TVR) and MACE (combination of cardiac death, target vessel MI and TLR).
Results
During the study period, 351 patients (with 414 lesions) with de novo lesions were treated with an SCB. The mean age of patients was 65.6±11.5 years, 275 (78%) were male and 39% (n=212) had diabetes. Most lesions treated were in the LAD/diagonal system (n=173, 42%). Predilatation was performed in 98% (405 lesions). Bailout stenting (with a drug eluting stent) was required in 7% lesions (n=30), of which 11 were due to dissections and 19 were due to recoil >50% following DCB use. The mean diameter and length of DCBs were 2.47 mm and 26 mm respectively.
During a median follow-up of 322-days (11-months) cardiac death was reported in 8 patients (2.3%). Target vessel MI was in 3%; n=10, TLR and TVR per lesion were 8% (n=34) and 9% (n=37) respectively. The MACE rate was 11%. There were no documented cases of acute vessel closure.
Conclusion
The mid-term outcome from the first ever study on sirolimus coated balloons in de novo lesions appears promising with low rates of hard endpoints with no documented cases of acute vessel closure. The MACE rates appear promising, although we need longer follow-up which is ongoing and we will be able to report outcomes from even longer follow-up during the presentation.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
| | - H Kalkat
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - A Saif
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - A M Fawzy
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - S Athulorala
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - G Bhatia
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - N Kumar
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - B Freestone
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - J Ment
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - K Lee
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - M Pitt
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | - G Pulikal
- Birmingham Heartlands Hospital, Birmingham, United Kingdom
| | | |
Collapse
|
6
|
Basavarajaiah S, Athukorala S, Kalogeras K, Panoulas V, Loku Waduge BH, Bhatia G, Watkin R, Pulikal G, Lee K, Ment J, Freestone B, Pitt M. Mid-term clinical outcomes from use of Sirolimus coated balloon in coronary intervention; data from real world population. Catheter Cardiovasc Interv 2021; 98:57-65. [PMID: 32473075 DOI: 10.1002/ccd.28998] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/03/2020] [Accepted: 05/12/2020] [Indexed: 11/10/2022]
Abstract
BACKGROUND Use of drug coated balloons (DCBs) in coronary intervention is escalating. There is a plethora of data on Paclitaxcel-DCB. However, when it comes of stents, Limus-drugs are preferred over Paclitaxel. There is very limited data on Sirolimus coated balloons (SCB). MagicTouch-SCB (Concept Medical, FL) elutes Sirolimus via nano-technology and have been used in our centers since March 2018. We report a mid-term follow-up with this relatively novel-technology. METHODS AND RESULTS We retrospectively analyzed all patients treated with MagicTouch-SCB between March-2018 and February-2019. Results are reported as cardiac-death, target-vessel myocardial-infarction (TVMI), target lesion revascularization (TLR) and Major Adverse Cardiac Events (MACE). During the study period, 288-patients (373-lesions) with a mean age of 65.8 were treated with MagicTouch-SCB. 84% (n = 241) were male, 155 (54%) were in the setting of acute coronary syndrome, 38% (n = 110) had diabetes and 62% (n = 233) were in de-novo lesions. Most lesions treated were in the LAD/diagonal-system (n = 170; 46%). Pre-dilatation was performed in 92% (n = 345) of cases. Bailout stenting was required in 9% lesions (n = 35). The mean diameter and length of SCBs were 2.64 ± 0.56 mm and 24 ± 8.9 mm respectively. During a median follow-up of 363 days (IQR: 278-435), cardiac death and TVMI occurred in 5-patients (1.7%) and 10-patients (3.4%) respectively, TLR per-lesion was 12%. The MACE rate was 10%. There were no documented cases of acute vessel closure. CONCLUSIONS The results from mid-term follow-up with this relatively new technology SCB is encouraging with a low rates of hard endpoints and acceptable MACE rates despite complex group of patients and lesion subsets.
Collapse
Affiliation(s)
| | | | | | | | | | - Gurbir Bhatia
- Heartlands Hospital, University Hospitals Birmingham, Birmingham, UK
| | - Richard Watkin
- Heartlands Hospital, University Hospitals Birmingham, Birmingham, UK
| | - George Pulikal
- Heartlands Hospital, University Hospitals Birmingham, Birmingham, UK
| | - Kaeng Lee
- Heartlands Hospital, University Hospitals Birmingham, Birmingham, UK
| | - Jerome Ment
- Heartlands Hospital, University Hospitals Birmingham, Birmingham, UK
| | - Bethan Freestone
- Heartlands Hospital, University Hospitals Birmingham, Birmingham, UK
| | - Michael Pitt
- Heartlands Hospital, University Hospitals Birmingham, Birmingham, UK
| |
Collapse
|
7
|
Basavarajaiah S, Mitomo S, Nakamura S, Sharma V, Mohammed I, Watanabe Y, Ouchi T, Bhatia G, Ment J, Athukorala S, Pitt M, Pulikal G, Freestone B, Rides H, Kumar N, Watkin R, Lee K. Long-term Outcome following Percutaneous Intervention of Intra-stent Coronary Occlusion and Evaluating the Different Treatment Modalities. Int J Cardiol Heart Vasc 2021; 34:100803. [PMID: 34222612 PMCID: PMC8245734 DOI: 10.1016/j.ijcha.2021.100803] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2021] [Revised: 05/03/2021] [Accepted: 05/17/2021] [Indexed: 11/30/2022]
Abstract
Limited data on intra-stent CTO. We explored the long-term outcomes in patients undergoing PCI to intra-stent CTO. Acceptable rates of hard endpoints (cardiac death; 5.8%, TVMI; 4%). High rates of TLR (45.6%). PCI should only be undertaken if symptomatic or if there is inducible ischaemia. If PCI is undertaken, DCB and DES should be considered over POBA.
Background Angioplasty for ISR remains a challenge with relatively high rates of recurrence. Although there is a plethora of data on ISR, there is relatively less data on intra-stent-CTO. In this study, we explore the long-term clinical outcomes following angioplasty to intra-stent CTO and study the differences in clinical outcomes between three treatment-arms: POBA vs. DES vs. DCB. Methods and results We evaluated all patients who underwent PCI to intra-stent CTO between 2011 and 2017. The endpoints used were: cardiac-death, TVMI, TLR, TVR, and MACE. During the study period, 403-patients with a mean age of 69.2 years had successful PCI to intra-stent CTO. 50% were diabetic, 38% had CKD and 32% had left ventricular dysfunction. 93% of cases were stable angina. 22% (n = 88) received only POBA, 28% (n = 113) received DCB and 50% (n = 202) received DES. During the median follow-up of 48-months, cardiac-death occurred in 5.8% (n = 23), TVMI in 4% (n = 16), TLR in 45.6% (n = 182), TVR in 48.7% (n = 194) and MACE of 46%. There were no differences in the hard endpoints between the 3treatment arms. However, the TLR and overall MACE were better in DCB and DES-groups as compared to POBA (TLR: 33%vs.42%vs.49%; p = 0.06); MACE (34% vs. 45% vs. 52%; p = 0.05). Conclusion This is the first study that has focussed on the outcomes following angioplasty to intra-stent CTOs with a very long-term follow-up. The hard endpoints were low, although the TLR rates were high. In regards to treatment strategy, the DCB and DES provide relatively better outcomes than POBA.
Collapse
Key Words
- CKD, Chronic kidney disease
- CTO, Chronic total occlusion
- Chronic total occlusion
- DCB, Drug coated balloon
- DES, Drug eluting stent
- Drug coated balloon
- Drug eluting stent
- ISR, In-stent restenosis
- In-stent restenosis
- LVSD, Left ventricular dysfunction
- MACE, Major adverse cardiac events
- POBA, Plain old balloon angioplasty
- TLR, Target lesion revascularisation
- TVMI, Target vessel myocardial infarction
- TVR, Target vessel revascularisation
Collapse
Affiliation(s)
| | | | | | | | - Ishaq Mohammed
- Heartlands Hospital, University Hospitals Birmingham, United Kingdom
| | - Yusuke Watanabe
- Heartlands Hospital, University Hospitals Birmingham, United Kingdom
| | | | - Gurbir Bhatia
- Heartlands Hospital, University Hospitals Birmingham, United Kingdom
| | - Jerome Ment
- Heartlands Hospital, University Hospitals Birmingham, United Kingdom
| | | | - Michael Pitt
- Heartlands Hospital, University Hospitals Birmingham, United Kingdom
| | - George Pulikal
- Heartlands Hospital, University Hospitals Birmingham, United Kingdom
| | - Bethan Freestone
- Heartlands Hospital, University Hospitals Birmingham, United Kingdom
| | - Hannah Rides
- Heartlands Hospital, University Hospitals Birmingham, United Kingdom
| | - Nitin Kumar
- Heartlands Hospital, University Hospitals Birmingham, United Kingdom
| | - Richard Watkin
- Heartlands Hospital, University Hospitals Birmingham, United Kingdom
| | - Kaeng Lee
- Heartlands Hospital, University Hospitals Birmingham, United Kingdom
| |
Collapse
|
8
|
Athukorala S, El-Shiekh M, Mohammed I, Watkin R, Bhatia G, Ment J, Lee K. TCT-272 Incidence and Outcomes of Bailout Stenting Following Use of Drug-Coated Balloon. J Am Coll Cardiol 2019. [DOI: 10.1016/j.jacc.2019.08.344] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
9
|
Abstract
Atrial fibrillation (AF) is the most common cardiac arrhythmia worldwide. Strokes that occur as a complication of AF are usually more severe and associated with a higher disability or morbidity and mortality rate compared with non-AF-related strokes. The risk of stroke in AF is dependent on several risk factors; AF itself acts as an independent risk factor for stroke. The combination of effective anticoagulation therapy, risk stratification (based on stroke risk scores, such as CHADS2 and CHA2DS2-VASc), and recommendations provided by guidelines is essential for decreasing the risk of stroke in patients with AF. Although effective in preventing the occurrence of stroke, vitamin K antagonists (VKAs; eg, warfarin) are associated with several limitations. Therefore, direct oral anticoagulants, such as apixaban, dabigatran etexilate, edoxaban, and rivaroxaban, have emerged as an alternative to the VKAs for stroke prevention in patients with nonvalvular AF. Compared with the VKAs, these agents have more favorable pharmacological characteristics and, unlike the VKAs, they are given at fixed doses without the need for routine coagulation monitoring. It remains important that physicians use these direct oral anticoagulants responsibly to ensure optimal safety and effectiveness. This article provides an overview of the existing data on the direct oral anticoagulants, focusing on management protocols for aiding physicians to optimize anticoagulant therapy in patients with nonvalvular AF, particularly in special patient populations (eg, those with renal impairment) and other specific clinical situations.
Collapse
Affiliation(s)
- Jerome Ment
- Department of Cardiology, Birmingham Heartlands Hospital, Birmingham, UK
| |
Collapse
|
10
|
Lewis G, Hoey ETD, Reynolds JH, Ganeshan A, Ment J. Multi-detector CT assessment in pulmonary hypertension: techniques, systematic approach to interpretation and key findings. Quant Imaging Med Surg 2015; 5:423-32. [PMID: 26029645 DOI: 10.3978/j.issn.2223-4292.2015.01.05] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2014] [Accepted: 01/22/2015] [Indexed: 01/03/2023]
Abstract
Pulmonary arterial hypertension (PAH) may be suspected based on the clinical history, physical examination and electrocardiogram findings but imaging is usually central to confirming the diagnosis, establishing a cause and guiding therapy. The diagnostic pathway of PAH involves a variety of complimentary investigations of which computed tomography pulmonary angiography (CTPA) has established a central role both in helping identify an underlying cause for PAH and assessing resulting functional compromise. In particular CTPA is considered as the gold standard technique for the diagnosis of thromboembolic disease. This article reviews the CTPA evaluation in PAH, describing CTPA techniques, a systematic approach to interpretation and spectrum of key imaging findings.
Collapse
Affiliation(s)
- Gareth Lewis
- 1 Department of Radiology, 2 Department of Cardiology, Heart of England NHS Trust, Birmingham, UK
| | - Edward T D Hoey
- 1 Department of Radiology, 2 Department of Cardiology, Heart of England NHS Trust, Birmingham, UK
| | - John H Reynolds
- 1 Department of Radiology, 2 Department of Cardiology, Heart of England NHS Trust, Birmingham, UK
| | - Arul Ganeshan
- 1 Department of Radiology, 2 Department of Cardiology, Heart of England NHS Trust, Birmingham, UK
| | - Jerome Ment
- 1 Department of Radiology, 2 Department of Cardiology, Heart of England NHS Trust, Birmingham, UK
| |
Collapse
|
11
|
Chue CD, Qaisar S, Ment J. Thrombus straddling a patent foramen ovale. Acute Card Care 2014; 16:135. [PMID: 25101657 DOI: 10.3109/17482941.2014.944540] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Affiliation(s)
- Colin D Chue
- Heart of England NHS Foundation Trust, Birmingham Heartlands Hospital , Birmingham , UK
| | | | | |
Collapse
|
12
|
Khan JN, Sanyal R, Pallan A, Ferrando J, Ment J, Roy-Choudhury S. Obstructive jaundice following a myocardial infarct: pseudoaneurysm of the gastroduodenal artery. Gut 2008; 57:180, 187. [PMID: 18192452 DOI: 10.1136/gut.2006.103804] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/08/2022]
Affiliation(s)
- J N Khan
- Heart of England NHS Foundation Trust, Bordesley Green East, Birmingham B9 5SS, UK
| | | | | | | | | | | |
Collapse
|
13
|
Abstract
Reported here is a case of Eikenella corrodens aortic valve infective endocarditis presenting as a stroke in a previously healthy 31-year-old man. The patient had no evidence of structural heart disease and reported no history of intravenous drug use or recent dental treatment. There are no other cases reported in the available literature in which this microorganism has caused endocarditis in the absence of recognised risk factors.
Collapse
Affiliation(s)
- R W Watkin
- Department of Cardiology, Queen Elizabeth Hospital, Edgbaston, Birmingham B5 2TH, UK,
| | | | | | | |
Collapse
|
14
|
|
15
|
Ayres JG, Wildman M, Groves J, Ment J, Smith EG, Beattie JM. Long-term follow-up of patients from the 1989 Q fever outbreak: no evidence of excess cardiac disease in those with fatigue. QJM 2002; 95:539-46. [PMID: 12145393 DOI: 10.1093/qjmed/95.8.539] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND In 1989, an outbreak of Q fever (C. burnetii infection) with 147 confirmed cases occurred in Solihull, West Midlands. Three patients developed cardiomyopathy in the subsequent 10 years. The cohort has been followed up with respect to the development of fatigue and, in this instance, cardiac effects after the original infection. AIM To determine whether persisting fatigue after Q fever represented sub-clinical cardiomyopathy. DESIGN Prospective follow-up study. METHODS All traceable subjects from the original outbreak, and community age-, sex- and smoking-matched controls, were studied. Questionnaires for idiopathic fatigue, 12-lead ECG, echocardiography, spirometry and shuttle walk distance were undertaken, and a subset with CDC-defined chronic fatigue syndrome had gated cardiac scans. RESULTS Of the original cohort, 19 had died, three had emigrated and 10 were untraceable. Of the remaining 115, 108 responded to a mailed questionnaire and 87 were investigated further, of whom 85 provided complete data. Two developed aortic valve vegetations, one of whom died. Chronic fatigue syndrome was found in 20% of cases and 5.3% of controls (including those with co-morbidities), falling to 8.2% and 0 when excluding those with co-morbidities. There were no significant differences in ECG and echocardiographic investigations or shuttle-walk distance between those with fatigue and those without. Six of the seven patients with CFS had gated cardiac scans: all were within normal limits. CONCLUSIONS These findings do not support the existence of a sub-clinical cardiomyopathy in the patients in this cohort who suffer from fatigue after acute Q fever, although endocarditis can occur after acute infection.
Collapse
Affiliation(s)
- J G Ayres
- Department of Respiratory Medicine, Birmingham Heartlands Hospital, Birmingham, UK.
| | | | | | | | | | | |
Collapse
|